Advanced Cell Technology is testing a stem-cell treatment for blindness that could preserve vision and potentially reverse vision loss.
Susan YoungFollow @twitterapi
I’m the biomedicine editor for MIT Technology Review. I look for stories where technology stands to improve human health or advance our understanding of the human condition.
I joined MIT Technology Review in March 2012 after a brief stint in the Washington, D.C., news bureau of the scientific journal Nature. Before I ventured to the East Coast, I spent several years in the San Francisco Bay Area as a doctoral student in molecular biology and one whirlwind year in science-writing boot camp in Santa Cruz.
In California, I wrote for the Stanford University press offices, the Multiple Sclerosis Discovery Forum, and the Salinas Californian newspaper. I grew up in a small town in eastern Texas, surrounded by bird song, rolling cattle fields, and lanky pine trees. When I’m not exploring health tech, you will probably find me cooking or giggling over an exceptional LOLcat.
Susan Young's Stories
Artificial tissue has always lacked a key ingredient: blood vessels. A new 3-D printing technique seems poised to change that.
Engineering a patient’s own immune cells to resist HIV could eliminate the need for lifelong antiretroviral therapies.
A single-molecule gene test requires much less DNA to identify cancer-causing mutations.
A molecular diagnosis gives doctors and patients better treatment options when suspicious lumps are found in the neck.
Researchers are testing whether high-throughput DNA sequencing can help screen out abnormal embryos during in vitro fertilization.
Macaques in China are the first primates born with genomes engineered by precision gene-targeting methods.
Harvard Bioscience spin-off is stepping up its production of synthetic tracheas to supply clinical trials.
By delivering gene therapies to patients before they go blind, doctors may be able to prevent the loss of many important light-detecting cells.
Illumina announces a new high-end sequencer made for “factory-scale” sequencing of human genomes.